Document 0332
 DOCN  M9460332
 TI    Treatment research priorities for human immunodeficiency virus
       infection.
 DT    9408
 AU    Pettinelli CB; Schnittman SM; Division of AIDS, National Institute of
       Allergy and Infectious; Disease, National Institutes of Health,
       Rockville, Maryland.
 SO    Infect Agents Dis. 1993 Oct;2(5):291-303. Unique Identifier : AIDSLINE
       MED/94228152
 AB    Viral infections such as with the human immunodeficiency virus (HIV)
       present difficult challenges for the development of effective antiviral
       therapies. These viruses depend on the host cell machinery for their
       existence, and interference with these processes typically interferes
       with other important host physiology. HIV presents other challenges as
       well because of its inherent pathogenic destruction of the immune
       system. It is the goal of HIV therapeutics to attempt to cure HIV
       infection, or if that is not possible, to stop HIV disease progression
       while preserving a high quality of life for HIV-infected individuals.
       This may be achieved through an effective combination of interference
       with the viral life cycle and the pathogenic processes, and by slowing
       or reversing the immunologic dysfunction that leads to the complications
       of HIV infection. Unprecedented progress has been made in understanding
       the virus and HIV disease pathogenesis. This knowledge has led to the
       identification of viral features that have become targets for
       therapeutic intervention. This article reviews the most important
       priorities of HIV treatment research for adult HIV-infected patients for
       the immediate future. These priorities include the following:
       development of new antiretroviral compounds and their application as
       both monotherapies and in combination therapy approaches; immune-based
       therapeutic approaches; and research and treatment for acute or primary
       HIV infections.
 DE    Antiviral Agents/THERAPEUTIC USE  Drug Therapy, Combination  Human  HIV
       Infections/*THERAPY  HIV-1  Immunotherapy  JOURNAL ARTICLE  REVIEW
       REVIEW, ACADEMIC

       SOURCE: National Library of Medicine.  NOTICE: This material may be
       protected by Copyright Law (Title 17, U.S.Code).